Sponsor

Alector Inc.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Alector Inc. appears in 6 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials6
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

6 shown
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseNCT05744401 · lead sponsor · 2023-01-04
TERMINATED
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874 · lead sponsor · 2021-01-22
COMPLETED
First in Human Study for Safety and Tolerability of AL003.NCT03822208 · lead sponsor · 2019-03-29
COMPLETED
A Phase I Study for Safety and Tolerability of AL002.NCT03635047 · lead sponsor · 2018-11-12
COMPLETED
Open-label Extension Study in Participants With Early Alzheimer's DiseaseNCT07105709 · collaborator · 2025-08-14
RECRUITING
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's DiseaseNCT06079190 · collaborator · 2023-10-20
TERMINATED

Sponsor roles

lead sponsor4
collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.